Clinical Study
No Prognostic Impact of p53 and P-Glycoprotein Expression in Patients with Diffuse Large B-Cell Lymphoma
Table 1
Clinical characteristics of the 108 patients according to p53 expression.
| | Variables | Immunostaining for p53 (no.) | -value | | 0–2+ | 3+ |
| | Age group | | | 0.69 | | ≤60 years | 20 | 47 | | | >60 years | 10 | 31 | | | Sex | | | 0.68 | | Male | 17 | 39 | | | Female | 13 | 39 | | | B symptoms | | | 0.67 | | Absent | 16 | 47 | | | Present | 14 | 31 | | | Bulky mass (>6 cm) | | | 0.39 | | Absent | 25 | 57 | | | Present | 5 | 21 | | | Extranodal involvement | | | 0.86 | | Absent | 11 | 29 | | | Present | 19 | 49 | | | Serum LDH level | | | 0.90 | | Normal | 13 | 31 | | | High | 17 | 47 | | | Ann Arbor staging system | | | 0.12 | | II | 11 | 37 | | | III | 12 | 16 | | | IV | 7 | 25 | | | ECOG performance status | | | 0.46 | | 0-1 | 25 | 58 | | | 2–4 | 5 | 20 | | | International prognostic index | | | 0.85 | | Low | 8 | 15 | | | Low intermediate | 15 | 28 | | | High intermediate | 8 | 21 | | | High | 5 | 14 | |
|
|
